C-Met upregulates aquaporin 3 expression in human gastric carcinoma cells via the ERK signalling pathway

Cancer Letters

Volumn 319, Issue 1, 2012, Pages 109-117

  Wang, Jianping ^a,b   Gui, Zhifu ^a   Deng, Longying ^a   Sun, Maocai ^a   Guo, Renhua ^a   Zhang, Weiming ^a   Shen, Lizong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Yangzhong People's Hospital   (China)

Author keywords

Aquaporin 3; C Met; ERK; Gastric adenocarcinoma; Hepatocyte growth factor (HGF)

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; AQUAPORIN 3; MITOGEN ACTIVATED PROTEIN KINASE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER INVASION; CANCER TISSUE; CARCINOMA CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; TISSUE DIFFERENTIATION; UPREGULATION;

ADENOCARCINOMA; AQUAPORIN 3; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84862793908     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.12.040     Document Type: Article

References (36)

1. Arkenau H.T. Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J. Cancer Res. Clin. Oncol. 2009, 135:855-866.
2. Bladt F., Riethmacher D., Isenmann S., Aguzzi A., Birchmeier C. Essential role for the c-Met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995, 376:768-771.
3. Andermarcher E., Surani M.A., Gherardi E. Co-expression of the HGF/SF and c-Met genes during early mouse embryogenesis precedes reciprocal expression in adjacent tissues during organogenesis. Dev. Genet. 1996, 18:254-266.
4. Schmidt C., Bladt F., Goedecke S., Brinkmann V., Zschiesche W., Sharpe M., Gherardi E., Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995, 373:699-702.
5. Inoue T., Kataoka H., Goto K., Nagaike K., Igami K., Naka D., Kitamura N., Miyazawa K. Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 2004, 95:803-808.
6. Amemiya H., Kono K., Itakura J., Tang R.F., Takahashi A., An F.Q., Kamei S., Iizuka H., Fujii H., Matsumoto Y. C-Met expression in gastric cancer with liver metastasis. Oncology 2002, 63:286-296.
7. Wang J.Y., Hsieh J.S., Chen C.C., Tzou W.S., Cheng T.L., Chen F.M., Huang T.J., Huang Y.S., Huang S.Y., Yang T., Lin S.R. Alterations of APC, c-Met, and p53 genes in tumor tissue and serum of patients with gastric cancers. J. Surg. Res. 2004, 120:242-248.
8. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Jänne P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
9. Tang M.K., Zhou H.Y., Yam J.W., Wong A.S. C-Met overexpression contributes to the acquired apoptotic resistance of nonadherent ovarian cancer cells through a cross talk mediated by phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2. Neoplasia 2010, 12:128-138.
10. Comoglio P.M., Giordano S., Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug. Discov. 2008, 7:504-516.
11. Cai Z.W., Wei D., Schroeder G.M., Cornelius L.A., Kim K., Chen X.T., Schmidt R.J., Williams D.K., Tokarski J.S., An Y., Sack J.S., Manne V., Kamath A., Zhang Y., Marathe P., Hunt J.T., Lombardo L.J., Fargnoli J., Borzilleri R.M. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. Bioorg. Med. Chem. Lett. 2008, 18:3224-3229.
12. Xie B., Xing R., Chen P., Gou Y., Li S., Xiao J., Dong J. Down-regulation of c-Met expression inhibits human HCC cells growth and invasion by RNA interference. J. Surg. Res. 2009, 162:231-238.
13. Wang Z.X., Lu B.B., Yang J.S., Wang K.M., De W. Adenovirus-mediated SiRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells. J. Surg. Res. 2010, 171:127-135.
14. Chu S.H., Feng D.F., Zhang H., Chen E.T., Duan Z.X., Li X.Y., Li J., Ma Y.B., Zhu Z.A., Qiu J.H. C-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J. Neurooncol. 2009, 93:183-189.
15. Crosswell H.E., Dasgupta A., Alvarado C.S., Watt T., Christensen J.G., De P., Durden D.L., Findley H.W. PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer 2009, 9:411.
16. Matsumoto K., Nakamura T. NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics. Cancer. Sci. 2003, 94:321-327.
17. Ueda K., Iwahashi M., Matsuura I., Nakamori M., Nakamura M., Ojima T., Naka T., Ishida K., Matsumoto K., Nakamura T., Yamaue H. Adenoviral-mediated gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur. J. Cancer 2004, 40:2135-2142.
18. Buchanan S.G., Hendle J., Lee P.S., Smith C.R., Bounaud P.Y., Jessen K.A., Tang C.M., Huser N.H., Felce J.D., Froning K.J., Peterman M.C., Aubol B.E., Gessert S.F., Sauder J.M., Schwinn K.D., Russell M., Rooney I.A., Adams J., Leon B.C., Do T.H., Blaney J.M., Sprengeler P.A., Thompson D.A., Smyth L., Pelletier L.A., Atwell S., Holme K., Wasserman S.R., Emtage S., Burley S.K., Reich S.H. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo. Mol. Cancer. Ther. 2009, 8:3181-3190.
19. Pan B.S., Chan G.K., Chenard M., Chi A., Davis L.J., Deshmukh S.V., Gibbs J.B., Gil S., Hang G., Hatch H., Jewell J.P., Kariv I., Katz J.D., Kunii K., Lu W., Lutterbach B.A., Paweletz C.P., Qu X., Reilly J.F., Szewczak A.A., Zeng Q., Kohl N.E., Dinsmore C.J. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor. Cancer Res. 2010, 70:1524-1533.
20. Agre P. The aquaporin water channels. Proc. Am. Thorac. Soc. 2006, 3:5-13.
21. Magni F., Sarto C., Ticozzi D., Soldi M., Bosso N., Mocarelli P., Kienle M.G. Proteomic knowledge of human aquaporins. Proteomics 2006, 6:5637-5649.
22. Procino G., Mastrofrancesco L., Mira A., Tamma G., Carmosino M., Emma F., Svelto M., Valenti G. Aquaporin 2 and apical calcium-sensing receptor: new players in polyuric disorders associated with hypercalciuria. Semin. Nephrol. 2008, 28:297-305.
23. Li H., Kamiie J., Morishita Y., Yoshida Y., Yaoita E., Ishibashi K., Yamamoto T. Expression and localization of two isoforms of AQP10 in human small intestine. Biol. Cell 2005, 97:823-829.
24. Itoh T., Rai T., Kuwahara M., Ko S.B., Uchida S., Sasaki S., Ishibashi K. Identification of a novel aquaporin, AQP12, expressed in pancreatic acinar cells. Biochem. Biophys. Res. Commun. 2005, 330:832-838.
25. Hu J., Verkman A.S. Increased migration and metastatic potential of tumor cells expressing aquaporin water channels. Faseb. J. 2006, 20:1892-1894.
26. Hara-Chikuma M., Verkman A.S. Prevention of skin tumorigenesis and impairment of epidermal cell proliferation by targeted aquaporin-3 gene disruption. Mol. Cell. Biol. 2008, 28:326-332.
27. Xu H., Zhang Y., Wei W., Shen L., Wu W. Differential expression of aquaporin-4 in human gastric normal and cancer tissues. Gastroenterol. Clin. Biol. 2009, 33:72-76.
28. Shen L., Zhu Z., Huang Y., Shu Y., Sun M., Xu H., Zhang G., Guo R., Wei W., Wu W. Expression profile of multiple aquaporins in human gastric carcinoma and its clinical significance. Biomed. Pharmacother. 2010, 64:313-318.
29. Huang Y., Zhu Z., Sun M., Wang J., Guo R., Shen L., Wu W. Critical role of aquaporin-3 in the human epidermal growth factor-induced migration and proliferation in the human gastric adenocarcinoma cells. Cancer Biol. Ther. 2010, 9:1000-1007.
30. Maulik G., Shrikhande A., Kijima T., Ma P.C., Morrison P.T., Salgia R. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine. Growth Factor Rev. 2002, 13:41-59.
31. Drebber U., Baldus S.E., Nolden B., Grass G., Bollschweiler E., Dienes H.P., Hölscher A.H., Mönig S.P. The overexpression of c-Met as a prognostic indicator for gastric carcinoma compared to p53 and p21 nuclear accumulation. Oncol. Rep. 2008, 19:1477-1483.
32. Nakajima M., Sawada H., Yamada Y., Watanabe A., Tatsumi M., Yamashita J., Matsuda M., Sakaguchi T., Hirao T., Nakano H. The prognostic significance of amplification and overexpression of c-Met and c-erb B-2 in human gastric carcinomas. Cancer 1999, 85:1894-1902.
33. Wu C.W., Li A.F., Chi C.W., Chung W.W., Liu T.Y., Lui W.Y., P'eng F.K. Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma. Oncol. Rep. 1998, 5:817-822.
34. Yokozaki H., Yasui W., Tahara E. Genetic and epigenetic changes in stomach cancer. Int. Rev. Cytol. 2001, 204:49-95.
35. Mariotti M., Castiglioni S., Maier J.A. Inhibition of T24 human bladder carcinoma cell migration by RNA interference suppressing the expression of HD-PTP. Cancer. Lett. 2009, 273:155-163.
36. Cui B., Johnson S.P., Bullock N., Ali-Osman F., Bigner D.D., Friedman H.S. Decoupling of DNA damage response signaling from DNA damages underlies temozolomide resistance in glioblastoma cells. J. Biomedical. Res. 2010, 6:424-435.